Endothelial Sp1/Sp3 are essential to the effect of captopril on blood pressure in male mice

Hanlin Lu, Xiuxin Jiang, Lifan He, Xuyang Ji, Xinyun Li, Shaozhuang Liu, Yuanyuan Sun, Xiaoteng Qin, Xiwen Xiong, Sjaak Philipsen, Bo Xi, Meng Zhang, Jianmin Yang, Cheng Zhang, Yun Zhang and Wencheng Zhang ()
Additional contact information
Hanlin Lu: Qilu Hospital of Shandong University
Xiuxin Jiang: Shandong University
Lifan He: Qilu Hospital of Shandong University
Xuyang Ji: Qilu Hospital of Shandong University
Xinyun Li: Qilu Hospital of Shandong University
Shaozhuang Liu: Shandong University
Yuanyuan Sun: Qilu Hospital of Shandong University
Xiaoteng Qin: Qilu Hospital of Shandong University
Xiwen Xiong: Xinxiang Medical University
Sjaak Philipsen: Erasmus MC
Bo Xi: Shandong University
Meng Zhang: Qilu Hospital of Shandong University
Jianmin Yang: Qilu Hospital of Shandong University
Cheng Zhang: Qilu Hospital of Shandong University
Yun Zhang: Qilu Hospital of Shandong University
Wencheng Zhang: Qilu Hospital of Shandong University

Nature Communications, 2023, vol. 14, issue 1, 1-17

Abstract: Abstract Endothelial dysfunction represents a major cardiovascular risk factor for hypertension. Sp1 and Sp3 belong to the specificity protein and Krüppel-like transcription factor families. They are ubiquitously expressed and closely associated with cardiovascular development. We investigate the role of Sp1 and Sp3 in endothelial cells in vivo and evaluate whether captopril, an angiotensin-converting enzyme inhibitor (ACEI), targets Sp1/Sp3 to exert its effects. Inducible endothelial-specific Sp1/Sp3 knockout mice are generated to elucidate their role in endothelial cells. Tamoxifen-induced deletion of endothelial Sp1 and Sp3 in male mice decreases the serum nitrite/nitrate level, impairs endothelium-dependent vasodilation, and causes hypertension and cardiac remodeling. The beneficial actions of captopril are abolished by endothelial-specific deletion of Sp1/Sp3, indicating that they may be targets for ACEIs. Captopril increases Sp1/Sp3 protein levels by recruiting histone deacetylase 1, which elevates deacetylation and suppressed degradation of Sp1/Sp3. Sp1/Sp3 represents innovative therapeutic target for captopril to prevent cardiovascular diseases.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41567-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41567-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41567-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().